Western Union Wins FinTech Breakthrough Award for “Consumer Payments Innovation”
16.3.2021 15:05:00 EET | Business Wire | Press release
The Western Union Company (NYSE: WU), a global leader in cross-border, cross-currency money movement and payments, today was named winner of the “Consumer Payments Innovation Award” in the fifth annual FinTech Breakthrough Awards for 2021. The company’s innovative cross-border money transfer solution was awarded for its ‘plug and play’ technology used by a growing number of financial institutions to offer seamless, convenient, reliable, and fast international money transfer capabilities for their customers, connecting them to more than 200 countries and territories and over 130 currencies.
Western Union’s White Label Digital Partner technology solution enables FIs to use their existing branded customer technological interface to provide international money transfer services. FI’s customers can fund the transfers drawing from their linked bank accounts, wallets, or cards and choose to pay their receivers through the world’s widest-reaching networks, operated by Western Union, accessing billions of bank accounts, millions of digital wallets, and cards, and over half a million retail locations.
The FinTech Breakthrough Awards is the premier awards program founded to recognize the FinTech innovators, leaders, and visionaries worldwide in various categories, including Digital Banking, Personal Finance, Lending, Payments, Investments, RegTech, InsurTech, and many more. The 2021 FinTech Breakthrough Award program attracted more than 3,850 nominations from across the world.
“Western Union continues to deliver stellar customer experiences for consumers and businesses, moving money around the world every day, simplifying international money transfer complexities, including compliance, regulatory control, and settlement in over 130 currencies. Western Union has taken decades of innovation in serving its own branded customers and is now offering this functionality in a breakthrough white-label arrangement, driving even more cross-border connections for the wider financial sector,” said James Johnson, Managing Director, FinTech Breakthrough.
FinTech Breakthrough Awards perform the most in-depth evaluation of the sector to recognize the creativity, hard work, and success of innovative FinTech companies, technologies, and products worldwide.
“We are thrilled with the 2021 FinTech Breakthrough Award win and are honored with the recognition for our innovative cross-border money movement ‘plug and play’ capability, offered white label or branded as a part of our Digital Partner technology solution,” said Western Union President of Global Network, Jean Claude Farah.
Farah continued, “FI customers can initiate transactions from their bank website or mobile app and send directly to beneficiaries’ bank accounts, mobile wallets, cards, or for in-person cash pickup throughout Western Union’s leading global financial network bridging more than 200 countries and territories and over 130 currencies. With our Western Union Digital Partner technology solution, FIs can count on us to handle the cross-border payout of transactions seamlessly, in minutes, at scale, and in compliance with national and international regulations.”
The opening of Western Union’s cross-border platform and global financial network to third parties marks a strategic step to evolve Western Union to a diversified payments company, accessing adjacent cross-border money movement segments, and adding incremental customers.
FIs and the customers they serve no longer need to be confined to expensive, unpredictable, traditional cross-border payment channels. Western Union’s solution keeps the customer experience firmly in the hands of the FI - from the user interface to branding to pricing - while Western Union takes care of the complexities of the cross-border payout to the beneficiary. Additionally, Western Union’s robust compliance and risk ecosystem supports partners with sanctions and interdiction screening, and real-time risk assessment to detect and prevent fraud while also meeting local regulatory requirements for payouts.
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows, and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect businesses, financial institutions, governments, and consumers through one of the world’s widest-reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and over half a million retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com.
About FinTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for technology innovation and leadership around the globe, the FinTech Breakthrough Awards program is devoted to honoring excellence in Financial Technologies and Services companies and products. The FinTech Breakthrough Awards provide public recognition for the achievements of FinTech companies and products in categories including Payments, Personal Finance, Wealth Management, Fraud Protection, Banking, Lending, RegTech, InsurTech, and more. For more information, visit FinTechBreakthrough.com.
WU-G
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005405/en/
Contact information
Media Contact
Rachel Rogala, Western Union
Rachel.rogala@wu.com
+1 303-808-2674
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom